Ana Meliciano

Ms. Ana Meliciano

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2024 in Trends in Biotechnology
Verified
Journal Article
Closed access
ALAna F. Louro
Ana F. Louro
AMAna Meliciano
Ana Meliciano
PAPaula M Alves
Paula M Alves
MCMarta H.G. Costa
Marta H.G. Costa
MSMargarida Serra
Margarida Serra

15 March 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AMAna Meliciano
Ana Meliciano
DSDaniela Salvador
Daniela Salvador
PMPedro Mendonça
Pedro Mendonça
ALAna Filipa Louro
Ana Filipa Louro
MSMargarida Serra
Margarida Serra
The short shelf life of platelet concentrates (PC) of up to 5–7 days leads to higher wastage due to expiry. To address this massive financial burden on the healthcare system, alternative applications for expired PC have emerged in recent years. Engineered nanocarriers functionalized with platelet membranes have shown excellent targeting abilities for tumor cells owing to their platelet membrane proteins. Nevertheless, synthetic drug delivery strategies have significant drawbacks that platelet-derived extracellular vesicles (pEV) can overcome. We investigated, for the first time, the use of pEV as a carrier of the anti-breast cancer drug paclitaxel, considering it as an appealing alternative to improve the therapeutic potential of expired PC. The pEV released during PC storage showed a typical EV size distribution profile (100–300 nm) with a cup-shaped morphology. Paclitaxel-loaded pEV showed significant anti-cancer effects in vitro, as demonstrated by their anti-migratory (>30%), anti-angiogenic (>30%), and anti-invasive (>70%) properties in distinct cells found in the breast tumor microenvironment. We provide evidence for a novel application for expired PC by suggesting that the field of tumor treatment research may be broadened by the use of natural carriers.

31 March 2026 in Trends in Biotechnology
Verified
Journal Article
Closed access
AMAna Meliciano
Ana Meliciano
JJJoão Jacinto
João Jacinto
CFCatarina Freitas
Catarina Freitas
MCMarta H.G. Costa
Marta H.G. Costa
MFMiguel de Almeida Fuzeta
Miguel de Almeida Fuzeta
MSMargarida Serra
Margarida Serra

3 September 2025 in Biotechnology Journal
Verified
Journal Article
Open access
PVPedro Vicente
Pedro Vicente
AMAna Meliciano
Ana Meliciano
CDCláudia Diniz
Cláudia Diniz
ACArtemis Charalambidou
Artemis Charalambidou
ATAna Paula Terrasso
Ana Paula Terrasso
MSMargarida Serra
Margarida Serra
Human induced pluripotent stem cells (hiPSC) have great potential for cell therapy applications. To meet the global demand for hiPSC‐derived cell therapies, the implementation of scalable technologies, such as stirred‐tank bioreactors (STB), is essential. However, the addition of physical cues, including shear stress, can impact cell viability and proliferation and requires precise tuning. In this work, we used an engineering characterization approach to estimate the impeller power number (0.5) and investigate the mixing and suspension dynamics in the first generation of small‐scale (0.2 L) DASGIP bioreactors (DASGIP‐STB). By keeping constant power input per volume (P/V = 4.6 W/m3) as a scale‐up criteria, we successfully transferred a hiPSC expansion process to a 0.2 L single‐use STB (BioBLU‐STB) and scaled it up to a single‐use 2 L STB (Univessel‐STB) without compromising cell expansion, viability, and metabolism, as well as hiPSC quality attributes, including their pluripotent phenotype and differentiation potential.